1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Author
-
Burtness, Barbara, Harrington, Kevin J, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G M, Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D, Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael, Gan, Hui, Gao, Bo, Hughes, Brett, Mallesara, Girish, Rischin, Danny, Taylor, Anne, Burian, Martin, Fuereder, Thorsten, Greil, Richard, Barrios, Carlos Henrique, de Castro Junior, Dalvaro Oliveira, Castro, Gilberto, Franke, Fabio Andre, Girotto, Gustavo, Lima, Iane Pinto Figueiredo, Nicolau, Ulisses Ribaldo, Pinto, Gustavo Dix Junqueira, Santos, Lucas, Victorino, Ana-Paula, Chua, Neil, Couture, Felix, Gregg, Richard, Hansen, Aaron, Hilton, John, McCarthy, Joy, Soulieres, Denis, Ascui, Rodrigo, Gonzalez, Pablo, Villanueva, Luis, Torregroza, Marco, Zambrano, Angela, Holeckova, Petra, Kral, Zdenek, Melichar, Bohuslav, Prausova, Jana, Vosmik, Milan, Andersen, Maria, Gyldenkerne, Niels, Jurgens, Hannes, Putnik, Kadri, Reinikainen, Petri, Gruenwald, Viktor, Laban, Simon, Aravantinos, Gerasimos, Boukovinas, Ioannis, Georgoulias, Vassilis, Psyrri, Amanda, Kwong, Dora, Al-Farhat, Yousuf, Csoszi, Tibor, Erfan, Jozsef, Horvai, Geza, Landherr, Laszlo, Remenar, Eva, Ruzsa, Agnes, Szota, Judit, Billan, Salem, Gluck, Iris, Gutfeld, Orit, Popovtzer, Aron, Benasso, Marco, Bui, Simona, Ferrari, Vittorio, Licitra, Lisa, Nole, Franco, Fujii, Takashi, Fujimoto, Yasushi, Hanai, Nobuhiro, Hara, Hiroki, Matsumoto, Koji, Mitsugi, Kenji, Monden, Nobuya, Nakayama, Masahiro, Okami, Kenji, Oridate, Nobuhiko, Shiga, Kiyoto, Shimizu, Yasushi, Sugasawa, Masashi, Tahara, Makoto, Takahashi, Masanobu, Takahashi, Shunji, Tanaka, Kaoru, Ueda, Tsutomu, Yamaguchi, Hironori, Yamazaki, Tomoko, Yasumatsu, Ryuji, Yokota, Tomoya, Yoshizaki, Tomokazu, Kudaba, Iveta, Stara, Zinaida, Wan Ishak, Wan Zamaniah, Cheah, Soon Keat, Aguilar Ponce, Jose, Gonzalez Mendoza, Rene, Hernandez Hernandez, Carlos, Medina Soto, Francisco, Buter, Jan, Hoeben, Ann, Oosting, S., Suijkerbuijk, Karijn, Bratland, Aase, Brydoey, Marianne, Alvarez, Renzo, Mas, Luis, Caguioa, Priscilla, Querol, John, Regala, Eugenio Emmanuel, Tamayo, Maria Belen, Villegas, Ellie May, Kawecki, Andrzej, Karpenko, Andrey, Klochikhin, Arkadiy, Smolin, Alexey, Zarubenkov, Oleg, Goh, Boon Cher, Cohen, Graham, du Toit, Johanna, Jordaan, Christa, Landers, Gregory, Ruff, Paul, Szpak, Waldemar, Tabane, Neonyana, Brana, Irene, Iglesias Docampo, Lara, Lavernia, Javier, Mesia, Ricard, Abel, Edvard, Muratidu, Valentina, Nielsen, Niels, Cristina, Valerie, Rordorf, Tamara, Rothschild, Sacha, Hong, Ruey-Long, Wang, Hung-Ming, Yang, Muh-Hwa, Yeh, Su-Peng, Yen, Chia-Jui, Ngamphaiboon, Nuttapong, Soparattanapaisarn, Nopadol, Sriuranpong, Virote, Aksoy, Sercan, Cicin, Irfan, Ekenel, Meltem, Harputluoglu, Hakan, Ozyilkan, Ozgur, Harrington, Kevin, Agarwala, Sanjiv, Ali, Haythem, Alter, Robert, Anderson, Daniel, Bruce, Justine, Burtness, Barbara, Campbell, Nicholas, Conde, Miguel, Deeken, John, Edenfield, William, Feldman, Lawrence, Gaughan, Elizabeth, Goueli, Basem, Halmos, Balazs, Hegde, Upendra, Hunis, Brian, Jotte, Robert, Karnad, Anand, Khan, Saad, Laudi, Noel, Laux, Douglas, Martincic, Danko, McCune, Steven, McGaughey, Dean, Misiukiewicz, Krzysztof, Mulford, Deborah, Nadler, Eric, Neupane, Prakash, Nunnink, Johannes, Ohr, James, O'Malley, Meaghan, Patson, Brian, Paul, Doru, Popa, Elizabeta, Powell, Steven, Redman, Rebecca, Rella, Vincent, Rocha Lima, Chaio, Sivapiragasam, Abirami, Su, Yungpo, Sukari, Ammar, Wong, Stuart, Yilmaz, Emrullah, and Yorio, Jeffrey
- Abstract
Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.
- Published
- 2019
- Full Text
- View/download PDF